ERBB2 and breast cancer: HR‐positive/HER2‐negative breast cancer patients had the highest rate of nodal partial or mixed response, which was defined by the authors as heterogeneous response and could include the simultaneous presence of pathological complete response, partial response to metastases, and no response to metastases.